907 1030
[28]
Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830 – 4.[29]
Margel D, Yap SA, Lawrentschuk N, et al. Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassi fi cation among active surveillance candidates: a prospective cohort study. J Urol 2012;187:1247 – 52.[30]
Morgan VA, Riches SF, Thomas K, et al. Diffusion-weighted mag- netic resonance imaging for monitoring prostate cancer progres- sion in patients managed by active surveillance. Br J Radiol 2011;84:31 – 7.
[31]
Vargas HA, Akin O, Afaq A, et al. Magnetic resonance imaging for predicting prostate biopsy fi ndings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol 2012;188:1732 – 8.
[32]
Loeb S, Carlsson S, Braithwaite RS. Prostate cancer: modeling the outcomes of prostate cancer screening. Nat Rev Urol 2012;9:183 – 5.[33]
Shirk JD, Saigal CS. From QOL to QALYs: comparing nononcologic outcomes in prostate cancer survivors across treatments. Urol Oncol 2017;35:69 – 75.[34] Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy
or watchful waiting in early prostate cancer. N Engl J Med
2014;370:932
–
42
. http://dx.doi.org/10.1056/NEJMoa1311593.
[35]
Tosoian JJ, Carter HB, Lepor A, Loeb S. Active surveillance for prostate cancer: current evidence and contemporary state of prac- tice. Nat Rev Urol 2016;13:205 – 15.[36]
Dale W, Bilir SP, Hemmerich J, Basu A, Elstein A, Meltzer D. The prevalence, correlates, and impact of logically inconsistent prefer- ences in utility assessments for joint health states in prostate cancer. Med Care 2011;49:59 – 66.[37]
Alam R, Carter HB, Landis P, Epstein JI, Mamawala M. Conditional probability of reclassi fi cation in an active surveillance program for prostate cancer. J Urol 2015;193:1950 – 5.
[38]
Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Econ 2003;4: 143 – 50.
[39]
Shapiro RH, Johnstone PA. Risk of Gleason grade inaccuracies in prostate cancer patients eligible for active surveillance. Urology 2012;80:661 – 6.[40]
Inoue LY, Trock BJ, Partin AW, Carter HB, Etzioni R. Modeling grade progression in an active surveillance study. Stat Med 2014;33: 930 – 9.
[41]
Jain S, Loblaw A, Vesprini D, et al. Gleason upgrading with time in a large prostate cancer active surveillance cohort. J Urol 2015;194:79 – 84.
[42]
Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015;33:272 – 7.[43]
Musunuru HB, Yamamoto T, Klotz L, et al. Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunny- brook experience. J Urol 2016;196:1651 – 8.[44]
Popiolek M, Rider JR, Andren O, et al. Natural history of early, localized prostate cancer: a fi nal report from three decades of follow-up. Eur Urol 2013;63:428 – 35.[45]
Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without fl utamide for metastatic prostate cancer. N Engl J Med 1998;339:1036 – 42.[46]
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737 – 46.[47]
James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to fi rst-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163 – 77.
[48]
Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149 – 58.
[49]
Guo R, Cai L, Fan Y, Jin J, Zhou L, Zhang K. Magnetic resonance imaging on disease reclassi fi cation among active surveillance can- didates with low-risk prostate cancer: a diagnostic meta-analysis. Prostate Cancer Prostatic Dis 2015;18:221 – 8.[50]
Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015;313: 390 – 7.
[51]
de Rooij M, Hamoen EH, Futterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol 2014;202:343 – 51.
[52]
Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schroder FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012;61: 1110 – 4.[53]
Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of com- plications of prostate biopsy. Eur Urol 2013;64:876 – 92.[54]
Alibhai SM, Leach M, Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: in fl uence of age and comorbidity. J Natl Cancer Inst 2005;97:1525 – 32.
[55] US Preventive Services Task Force Draft Evidence Review for Pros-
tate Cancer Screening.
https://www.uspreventiveservicestaskforce. org/Page/Document/draft-evidence-review/ prostate-cancer-screening1 .[56]
Bremner KE, Chong CA, Tomlinson G, Alibhai SM, Krahn MD. A review and meta-analysis of prostate cancer utilities. Med Decis Making 2007;27:288 – 98.E U R O P E A N U R O L O GY 7 2 ( 2 0 17 ) 8 9 9
–
9 0 7
907